Premium
Pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions
Author(s) -
Thomas Kelan L. H.,
Ellingrod Vicki L.
Publication year - 2009
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.29.7.822
Subject(s) - pharmacogenetics , pharmacogenomics , drug class , drug , medicine , adverse effect , drug reaction , pharmacology , reuptake inhibitor , serotonin reuptake inhibitor , intensive care medicine , psychiatry , bioinformatics , antidepressant , genotype , biology , anxiety , genetics , gene
The selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely prescribed classes of drugs. They are relatively safe for the pharmacologic treatment of various psychiatric disorders; however, certain patients cannot tolerate some adverse drug reactions associated with this drug class. In addition, clinicians currently have no way to predict who will respond appropriately to a given SSRI, and the paradigm of trial and error is especially distressing for patients with mental illness. Pharmacogenetic association studies may provide insight into which genetic polymorphisms might be clinically relevant for individualizing pharmacotherapeutic regimens. Thus, we reviewed and summarized the literature regarding the pharmacogenomics of SSRI‐associated adverse drug reactions. This growing body of knowledge may inform subsequent design of pharmacogenetic studies with respect to adverse drug reactions. As we appreciate the many pharmacologic mechanisms related to adverse drug reactions and gain polymorphic functional data, we will have opportunities to refine hypotheses for future pharmacogenetic association analyses.